Simon Spichak finished his MSc at University College Cork, where he studied the interactions between the microbes in the gut and the brain. He became interested in science communication during his ...

The Food and Drug Administration is considering a rule change that would cut back on how often dietary supplement warnings must appear on packaging, a move experts say could make them easier to miss.

The internet is littered with unproven health supplements that use deceptive marketing and sales practices to trick victims into handing over their money. Not all health supplements are scams, but ...

Take a look in your medicine cabinet or pill box right now, and along with the medications prescribed by your doctor, you probably have at least a few vitamins and other supplements. Nearly 60 percent ...

If you purchase an independently reviewed product or service through a link on our website, Rolling Stone may receive an affiliate commission. Around the time people turn 30, they typically start to ...

Amanda is an editor at Health, where she edits condition-specific content to give readers access to the information they need to feel more empowered in their health. Allison Herries, RDN, is a ...

Short for gamma-aminobutyric acid, GABA is a naturally occurring amino acid that works as a calming neurotransmitter in the brain. “It helps regulate how our nervous system responds to stress by ...

Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.

Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? When your supplement stack starts taking up not one, but two shelves in your ...

(RTTNews) - Novartis (NVS,NOVN.SW) announced that its interleukin-17A inhibitor Cosentyx (secukinumab) met the primary and all secondary endpoints in the Phase III REPLENISH trial. The study evaluated ...

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.